Paper
Histamine receptors and COVID-19
Published Nov 18, 2020 · M. Ennis, K. Tiligada
Inflammation Research
38
Citations
0
Influential Citations
Abstract
ObjectiveReports that the over-the-counter histamine H_2 receptor antagonist famotidine could help treat the novel coronavirus disease (COVID-19) appeared from April 2020. We, therefore, examined reports on interactions between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and histamine receptor antagonists.MethodsA systematic literature search was performed by 19 September 2020, and updated on 28 October 2020, in PubMed, Scopus, Cochrane Library and Google Scholar using (COVID-19 OR coronavirus OR SARS-CoV-2) AND (histamine antagonist OR famotidine OR cimetidine). ClinicalTrials.gov was searched for COVID-19 and (famotidine or histamine).ResultsFamotidine may be a useful addition in COVID-19 treatment, but the results from prospective randomized trials are as yet awaited. Bioinformatics/drug repurposing studies indicated that, among several medicines, H_1 and H_2 receptor antagonists may interact with key viral enzymes. However, in vitro studies have to date failed to show a direct inhibition of famotidine on SARS-CoV-2 replication.ConclusionsClinical research into the potential benefits of H_2 receptor antagonists in managing COVID-19 inflammation began from a simple observation and now is being tested in multi-centre clinical trials. The positive effects of famotidine may be due to H_2 receptor-mediated immunomodulatory actions on mast cell histamine–cytokine cross-talk, rather than a direct action on SARS-CoV-2.
Systematic ReviewFamotidine may help treat COVID-19 by reducing inflammation through H2 receptor-mediated immunomodulation, rather than directly inhibiting SARS-CoV-2 replication.
Full text analysis coming soon...